Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/25/25	$27,000,000	Series B	Apollo Health Ventures Arkin Bio Ventures Brightedge Casdin Capital DCVC Franklin Berger Mubadala Capital Polaris Partners Qiming Venture Partners	undisclosed